-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Yangtze River Pharmaceutical Group's Jiangsu Longfengtang, a new Chinese medicine of category 1.
1, Qingchang Wenzhong Tablet, was approved for clinical use.
This new drug is an intestinal drug.
This is the second new Chinese medicine approved for clinical use in Yangtze River this year
.
According to data from Mi Nei.
com, in 2021, the market size of Chinese patent medicine intestinal medication is expected to exceed 1.
5 billion yuan in physical pharmacies in cities in China
.
1, Qingchang Wenzhong Tablet, was approved for clinical use.
This new drug is an intestinal drug.
This is the second new Chinese medicine approved for clinical use in Yangtze River this year
.
According to data from Mi Nei.
com, in 2021, the market size of Chinese patent medicine intestinal medication is expected to exceed 1.
5 billion yuan in physical pharmacies in cities in China
.
Figure 1: Yangtze River’s new TCM drugs approved for clinical use this year
Source: CDE official website
In April this year, Yangzijiang submitted a clinical application for a 2.
3-category Chinese medicine modified new medicine Sanfeng Tongqiao Dropping Pills, and the approved indication was seasonal allergic rhinitis
.
Qingchang Wenzhong Tablet is the first Chinese medicine class 1 new drug declared by the company this year.
The approved indication is for the treatment of ulcerative colitis with cold-heat complexes and damp-heat stasis syndrome
.
3-category Chinese medicine modified new medicine Sanfeng Tongqiao Dropping Pills, and the approved indication was seasonal allergic rhinitis
.
Qingchang Wenzhong Tablet is the first Chinese medicine class 1 new drug declared by the company this year.
The approved indication is for the treatment of ulcerative colitis with cold-heat complexes and damp-heat stasis syndrome
.
Figure 2: Sales of intestinal medications of proprietary Chinese medicines in physical pharmacies (unit: 10,000 yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
According to data from Mi Nei.
com, in the physical pharmacies of cities in China, the market size of intestinal medicines for proprietary Chinese medicines is more than 1 billion yuan.
The impact of the epidemic will decline slightly in 2020, and it is expected to exceed 1.
5 billion yuan in 2021
.
com, in the physical pharmacies of cities in China, the market size of intestinal medicines for proprietary Chinese medicines is more than 1 billion yuan.
The impact of the epidemic will decline slightly in 2020, and it is expected to exceed 1.
5 billion yuan in 2021
.
Table 1: 2021E entity pharmacy Chinese patent medicine intestinal medicine TOP5 varieties
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
In recent years, the sales of Changyanning in physical pharmacies in Chinese cities have steadily increased, and it is expected to become a new species exceeding 1 billion in 2021.
Currently, there are many Changyanning dosage forms on the market, involving tablets, capsules, granules, and pills.
, Oral liquid and syrup are mainly used to treat acute and chronic gastroenteritis, diarrhea, bacillary dysentery, and dyspepsia in children
.
Jiangxi Kangenbei Chinese Medicine is the leading enterprise of Changyanning, and its market share is expected to reach 90.
63% in 2021
.
Currently, there are many Changyanning dosage forms on the market, involving tablets, capsules, granules, and pills.
, Oral liquid and syrup are mainly used to treat acute and chronic gastroenteritis, diarrhea, bacillary dysentery, and dyspepsia in children
.
Jiangxi Kangenbei Chinese Medicine is the leading enterprise of Changyanning, and its market share is expected to reach 90.
63% in 2021
.
Source: CDE official website, Minet database
Note: Meinenet China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 cities and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Recently, Yangtze River Pharmaceutical Group's Jiangsu Longfengtang, a new Chinese medicine of category 1.
1, Qingchang Wenzhong Tablet, was approved for clinical use.
This new drug is an intestinal drug.
This is the second new Chinese medicine approved for clinical use in Yangtze River this year
.
According to data from Mi Nei.
com, in 2021, the market size of Chinese patent medicine intestinal medication is expected to exceed 1.
5 billion yuan in physical pharmacies in cities in China
.
1, Qingchang Wenzhong Tablet, was approved for clinical use.
This new drug is an intestinal drug.
This is the second new Chinese medicine approved for clinical use in Yangtze River this year
.
According to data from Mi Nei.
com, in 2021, the market size of Chinese patent medicine intestinal medication is expected to exceed 1.
5 billion yuan in physical pharmacies in cities in China
.
Figure 1: Yangtze River’s new TCM drugs approved for clinical use this year
Source: CDE official website
In April this year, Yangzijiang submitted a clinical application for a 2.
3-category Chinese medicine modified new medicine Sanfeng Tongqiao Dropping Pills, and the approved indication was seasonal allergic rhinitis
.
Qingchang Wenzhong Tablet is the first Chinese medicine class 1 new drug declared by the company this year.
The approved indication is for the treatment of ulcerative colitis with cold-heat complexes and damp-heat stasis syndrome
.
3-category Chinese medicine modified new medicine Sanfeng Tongqiao Dropping Pills, and the approved indication was seasonal allergic rhinitis
.
Qingchang Wenzhong Tablet is the first Chinese medicine class 1 new drug declared by the company this year.
The approved indication is for the treatment of ulcerative colitis with cold-heat complexes and damp-heat stasis syndrome
.
Figure 2: Sales of intestinal medications of proprietary Chinese medicines in physical pharmacies (unit: 10,000 yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
According to data from Mi Nei.
com, in the physical pharmacies of cities in China, the market size of intestinal medicines for proprietary Chinese medicines is more than 1 billion yuan.
The impact of the epidemic will decline slightly in 2020, and it is expected to exceed 1.
5 billion yuan in 2021
.
com, in the physical pharmacies of cities in China, the market size of intestinal medicines for proprietary Chinese medicines is more than 1 billion yuan.
The impact of the epidemic will decline slightly in 2020, and it is expected to exceed 1.
5 billion yuan in 2021
.
Table 1: 2021E entity pharmacy Chinese patent medicine intestinal medicine TOP5 varieties
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
In recent years, the sales of Changyanning in physical pharmacies in Chinese cities have steadily increased, and it is expected to become a new species exceeding 1 billion in 2021.
Currently, there are many Changyanning dosage forms on the market, involving tablets, capsules, granules, and pills.
, Oral liquid and syrup are mainly used to treat acute and chronic gastroenteritis, diarrhea, bacillary dysentery, and dyspepsia in children
.
Jiangxi Kangenbei Chinese Medicine is the leading enterprise of Changyanning, and its market share is expected to reach 90.
63% in 2021
.
Currently, there are many Changyanning dosage forms on the market, involving tablets, capsules, granules, and pills.
, Oral liquid and syrup are mainly used to treat acute and chronic gastroenteritis, diarrhea, bacillary dysentery, and dyspepsia in children
.
Jiangxi Kangenbei Chinese Medicine is the leading enterprise of Changyanning, and its market share is expected to reach 90.
63% in 2021
.
Source: CDE official website, Minet database
Note: Meinenet China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 cities and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Recently, Yangtze River Pharmaceutical Group's Jiangsu Longfengtang, a new Chinese medicine of category 1.
1, Qingchang Wenzhong Tablet, was approved for clinical use.
This new drug is an intestinal drug.
This is the second new Chinese medicine approved for clinical use in Yangtze River this year
.
According to data from Mi Nei.
com, in 2021, the market size of Chinese patent medicine intestinal medication is expected to exceed 1.
5 billion yuan in physical pharmacies in cities in China
.
1, Qingchang Wenzhong Tablet, was approved for clinical use.
This new drug is an intestinal drug.
This is the second new Chinese medicine approved for clinical use in Yangtze River this year
.
According to data from Mi Nei.
com, in 2021, the market size of Chinese patent medicine intestinal medication is expected to exceed 1.
5 billion yuan in physical pharmacies in cities in China
.
Figure 1: Yangtze River’s new TCM drugs approved for clinical use this year
Source: CDE official website
In April this year, Yangzijiang submitted a clinical application for a 2.
3-category Chinese medicine modified new medicine Sanfeng Tongqiao Dropping Pills, and the approved indication was seasonal allergic rhinitis
.
Qingchang Wenzhong Tablet is the first Chinese medicine class 1 new drug declared by the company this year.
The approved indication is for the treatment of ulcerative colitis with cold-heat complexes and damp-heat stasis syndrome
.
3-category Chinese medicine modified new medicine Sanfeng Tongqiao Dropping Pills, and the approved indication was seasonal allergic rhinitis
.
Qingchang Wenzhong Tablet is the first Chinese medicine class 1 new drug declared by the company this year.
The approved indication is for the treatment of ulcerative colitis with cold-heat complexes and damp-heat stasis syndrome
.
Figure 2: Sales of intestinal medications of proprietary Chinese medicines in physical pharmacies (unit: 10,000 yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
According to data from Mi Nei.
com, in the physical pharmacies of cities in China, the market size of intestinal medicines for proprietary Chinese medicines is more than 1 billion yuan.
The impact of the epidemic will decline slightly in 2020, and it is expected to exceed 1.
5 billion yuan in 2021
.
com, in the physical pharmacies of cities in China, the market size of intestinal medicines for proprietary Chinese medicines is more than 1 billion yuan.
The impact of the epidemic will decline slightly in 2020, and it is expected to exceed 1.
5 billion yuan in 2021
.
Table 1: 2021E entity pharmacy Chinese patent medicine intestinal medicine TOP5 varieties
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
In recent years, the sales of Changyanning in physical pharmacies in Chinese cities have steadily increased, and it is expected to become a new species exceeding 1 billion in 2021.
Currently, there are many Changyanning dosage forms on the market, involving tablets, capsules, granules, and pills.
, Oral liquid and syrup are mainly used to treat acute and chronic gastroenteritis, diarrhea, bacillary dysentery, and dyspepsia in children
.
Jiangxi Kangenbei Chinese Medicine is the leading enterprise of Changyanning, and its market share is expected to reach 90.
63% in 2021
.
Enterprise business enterpriseCurrently, there are many Changyanning dosage forms on the market, involving tablets, capsules, granules, and pills.
, Oral liquid and syrup are mainly used to treat acute and chronic gastroenteritis, diarrhea, bacillary dysentery, and dyspepsia in children
.
Jiangxi Kangenbei Chinese Medicine is the leading enterprise of Changyanning, and its market share is expected to reach 90.
63% in 2021
.
Source: CDE official website, Minet database
Note: Meinenet China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 cities and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Pharmacy pharmacy pharmacy .
The above sales are calculated based on the average retail price of the product at the terminal
.
